Immuneering
Biopharmaceutical company developing rhythm-based small-molecule therapies for oncology. The organization focuses on pulsatile (temporal) inhibition strategies targeting the MAPK pathway to improve durability of tumor control and tolerability. Activities include discovery and preclinical translational models, genomic biomarker research, computational biology and cloud analytics, clinical trial design and execution (Phase 1–3), CMC and clinical manufacturing, regulatory engagement, and external partnerships to enable combination studies and clinical supply.
Industries
Nr. of Employees
medium (51-250)
Immuneering
Patents
Products
Oral dual‑MEK inhibitor developed for pulsatile dosing (clinical candidate)
An orally dosed small-molecule MEK inhibitor engineered for rhythmic/pulsatile dosing to treat RAS‑ or RAF‑mutant solid tumors; evaluated as monotherapy and in combination with chemotherapy and PD‑1 inhibitors.
Phase 2‑ready MEK inhibitor asset (first‑in‑human characterized)
A MEK inhibitor asset characterized in a first‑in‑human ascending‑dose study with safety, tolerability and preliminary anti‑tumor activity defined and available for partnering discussions.
Oral dual‑MEK inhibitor developed for pulsatile dosing (clinical candidate)
An orally dosed small-molecule MEK inhibitor engineered for rhythmic/pulsatile dosing to treat RAS‑ or RAF‑mutant solid tumors; evaluated as monotherapy and in combination with chemotherapy and PD‑1 inhibitors.
Phase 2‑ready MEK inhibitor asset (first‑in‑human characterized)
A MEK inhibitor asset characterized in a first‑in‑human ascending‑dose study with safety, tolerability and preliminary anti‑tumor activity defined and available for partnering discussions.
Services
In-house execution of oncology clinical programs from early-phase dose-finding through global Phase 3 trials, including clinical operations, safety monitoring, and clinical data management.
Support for industry collaborations, clinical supply agreements and co-development partnerships to enable combination studies and external access to product candidates.
In-house execution of oncology clinical programs from early-phase dose-finding through global Phase 3 trials, including clinical operations, safety monitoring, and clinical data management.
Support for industry collaborations, clinical supply agreements and co-development partnerships to enable combination studies and external access to product candidates.
Expertise Areas
- Clinical trial management and global Phase 1–3 oncology programs
- Translational research and biomarker discovery
- Small-molecule oncology discovery targeting the MAPK pathway
- Genomic data science and NGS-based biomarker workflows
Key Technologies
- Pulsatile/temporal dosing strategies
- MEK inhibition targeting the MAPK pathway
- Humanized 3D tumor models
- Patient-derived xenograft (PDX) models
News & Updates
Phase 3 randomized open-label global trial evaluating the oral pulsatile MEK inhibitor in combination with modified gemcitabine and nab‑paclitaxel versus standard of care in first‑line metastatic pancreatic ductal adenocarcinoma (presentation at ESMO 2026).
Presentation of Phase 2a clinical results evaluating the pulsatile MEK inhibitor in combination with modified gemcitabine/nab‑paclitaxel in first‑line metastatic pancreatic cancer.
Press coverage and interview discussing Phase 2a clinical data for the pulsatile MEK inhibitor combined with chemotherapy in pancreatic cancer.
Coverage reporting updated clinical survival and tolerability data for the pulsatile MEK inhibitor combination in first‑line pancreatic cancer.
Initiation planning and first‑patient dosing anticipated/moving into a global Phase 3 study evaluating the pulsatile MEK inhibitor in first‑line metastatic pancreatic cancer.
A strategic equity investment was made to advance development of the company's product pipeline through a private placement transaction.
Phase 3 randomized open-label global trial evaluating the oral pulsatile MEK inhibitor in combination with modified gemcitabine and nab‑paclitaxel versus standard of care in first‑line metastatic pancreatic ductal adenocarcinoma (presentation at ESMO 2026).
Presentation of Phase 2a clinical results evaluating the pulsatile MEK inhibitor in combination with modified gemcitabine/nab‑paclitaxel in first‑line metastatic pancreatic cancer.
Press coverage and interview discussing Phase 2a clinical data for the pulsatile MEK inhibitor combined with chemotherapy in pancreatic cancer.
Coverage reporting updated clinical survival and tolerability data for the pulsatile MEK inhibitor combination in first‑line pancreatic cancer.
Initiation planning and first‑patient dosing anticipated/moving into a global Phase 3 study evaluating the pulsatile MEK inhibitor in first‑line metastatic pancreatic cancer.
A strategic equity investment was made to advance development of the company's product pipeline through a private placement transaction.